🔐 Our Commitment to Security As the Cetus incident unfolds we contacted our auditor @AsymptoticTech right away and asked about the impact of the exploit and if it would affect our own contract. It's confirmed that the core perpetual contract powering both @sudofinance and @zofaiperps is not using any relevant code that would be affected by the exploit. Our stance on the security has never changed - it's our first and foremost priority. Your fund is SAFE 🔒.

We are aware of recent developments around security within Sui Ecosystem. We have temporarily paused trading on CETUS/USD as a precautionary measure. Your fund is SAFE on Sudo. Please stay tuned for latest updates.

We do not stop shipping. While our metrics climbed across retail and institutional adoption this week, we are already gearing up for a massive upgrade next week that will completely change how value moves. Here is your weekly recap. • @Ledger reported Sui as a top trending asset with a 21.75% increase in weekly trading volume change inside the Ledger Wallet ecosystem. • @astros_ag revealed that users traded over $200M worth of TradFi assets within just seven days of launch, demonstrating massive appetite for 24/7 tokenized equities. • @CurrentSUI is now the home to one of the largest $USDsui supply on the network at $8.89M, maintaining a highly active 72% utilization rate. • @xMoney_com CEO @xMoneyGreg joined the latest Sui Builder Livestream hosted by @SuiCommunity to discuss how their protocol is changing real world crypto payments. • @InsightXnetwork launched Atlas Live, an exclusive real time holder map enabling users to trace funds and monitor token action live on Sui. • Sui engineers are currently on the ground in Reykjavik for EVE Fanfest collaborating with @EVE_Frontier to build moddable onchain civilization logistics. • @jussy_world highlighted the top 8 projects dominating major narratives on the network, spotlighting leaders like @WaterX_app, @CetusProtocol, and @navi_protocol. • Next week, onchain payments take a massive leap forward as gasless transfers are officially imminent on Sui.

Cets is giving bnb chain something it’s never had before. An organic community cult coin spanning both east and west. I think long term that’s worth a lot more than you think it is.

#ESMOGI2026# Surprising news for mCRC out of ESMOGI. KRYSTAL-10: Adagrasib + cetuximab misses its primary endpoint in 2L KRAS G12C mCRC. After the accelerated approval and encouraging activity from KRYSTAL-1, many expected dual KRAS/EGFR inhibition to outperform chemotherapy in the second line. That didn't happen. Quick hits: • Primary endpoint (PFS): Negative • mPFS 7.5 vs 8.1 months • HR 0.89 (95% CI 0.71-1.13) • Response rate dramatically improved • ORR 47% vs 16% • CR 7% vs <1% • No improvement in OS at the final analysis despite the higher response rate. So what happened? This is a reminder that response rate ≠ durable disease control. Nearly half of patients responded, but those responses did not translate into longer PFS or OS compared with modern chemotherapy. Targeted therapy works, but mCRC can overcome via resistance mechanisms (such as via massive KRAS upregulation). Will be interesting to see how novel degraders come into the mix here... Remember, this is a first gen KRASi, the future is still bright here. What does this mean for clinic tomorrow? Honestly, I still love a chemo-free option that is at least on par with chemotherapy. This isn't the end of KRAS G12C in CRC. Far from it. The focus now shifts to moving targeted therapy earlier, where combinations with chemotherapy may produce deeper, more durable responses before resistant clones emerge. Multiple frontline studies are already underway. @TheGutOncLab @OncoAlert @Onco_Nexus @myESMO